



Product Information

HIV protease inhibitor Nelfinavir mesylate, Purity $\geq 98\%$

Cat. No.: X24-07-ZQ787

Size: 10 mg; 25 mg; 50 mg; 100 mg


MDL: MFCD00931436

CAS Number: 159989-65-8

Compound CID: 64142

Synonym: 159989-65-8; HIV protease inhibitor

This product is for research use only and is not intended for diagnostic use.



Product Information

Description	Nelfinavir mesylate, soluble in DMSO and ethanol and insoluble in water, blocks the protease enzyme, essential for the maturation and replication of HIV, playing a key role in highly active antiretroviral therapy (HAART). It targets HIV protease.
Molecular Weight	663.89
Molecular Formula	C ₃₃ H ₄₉ N ₃ O ₇ S ₂
Targets	HIV protease: 2 nM (K _i)
IUPAC Name	(3 <i>S</i> ,4 <i>aS</i> ,8 <i>aS</i>)- <i>N</i> - <i>tert</i> -butyl-2-[(2 <i>R</i> ,3 <i>R</i>)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4 <i>a</i> ,5,6,7,8,8 <i>a</i> -octahydro-1 <i>H</i> -isoquinoline-3-carboxamide;methanesulfonic acid
InChI	InChI=1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1
InChI Key	NQHXCAXSHGTIA-SKXNDZRYSA-N
Canonical SMILES	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
Isomeric SMILES	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
Form	Lyophilized powder
Purity	$\geq 98\%$
Solubility	DMSO: 85 mg/mL (128.03 mM); Water: Insoluble; Ethanol: 85 mg/mL



Identity	Confirmed by NMR/HPLC/MS.
Stability	The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Quality Level	Research grade
Applications	Nelfinavir mesylate is used to explore its effects on inhibiting HIV protease, offering insights into antiretroviral therapy.
Storage	Store at -20°C, and keep desiccated.
